Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Coronary artery disease wikipedia , lookup
Electrocardiography wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
Remote ischemic conditioning wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Management of acute coronary syndrome wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Heart failure wikipedia , lookup
Heart arrhythmia wikipedia , lookup
Dextro-Transposition of the great arteries wikipedia , lookup
Dear editorial board of CARDIOLOGY JOURNAL Please find the manuscript: “Allogeneic mononuclear cells from human umbilical cord blood transplantation for chronic postinfarction heart failure: A 6-year follow-up study ” by Li-zhu, et al., to be submitted as a research article to CARDIOLOGY JOURNAL for consideration of publication. The manuscript was modified according to the suggestion of the reviewer point to point. This is a de novo submission. And the previous manuscript was 47229. All co-authors have seen and agree with the contents of the manuscript and there is no financial interest to report. We certify that the submission is original work and is not under review at any other publication. Clinical trials suggest a positive influence of autologous bone marrow mononuclear cells on myocardial infarction (MI) and heart failure. Very few studies have investigated the safety profile and efficacy of allogeneic umbilical cord blood mononuclear cells (CB-MNCs) administered intravenously to patients with chronic postinfarction heart failure. The present study reported a case of a 68-year-old man who was diagnosed with acute MI and severe heart failure in September 2008. Conventional drugs could not improve cardiac function 9 months post-MI. The heart function improved significantly after intravenous injection of CB-MNCs four times in July 2009. Echocardiography data showed a significant improvement in the indicators. The N-terminal pro-brain natriuretic peptide (NT-pro-BNP) level significantly reduced and was maintained at a relatively low level. The infarct size reduced by 11%. Six years after CB-MNC therapy, the parameters such as NT-pro-BNP, 6-min walking test, and left ventricular ejection fraction were relatively stable. This case indicated that an intravenous injection of CB-MNCs can significantly improve left ventricular performance, quality of life, and mortality of patients with heart failure caused by MI. This study was performed to assess the safety profile and efficacy of allogeneic CB-MNCs administered intravenously to patients with chronic postinfarction heart failure. The improvement in the heart function and the overall evaluation of vital signs indicated that allogeneic CB-MNC transplantation is safe and effective for patients with chronic postinfarction heart failure. This study provided the basis for more extensive and in-depth studies in the future to assess the role of allogeneic CB-MNCs in the treatment of chronic postinfarction heart failure. Author Contributions LZ collected umbilical cord, AY carried out isolation CB-MNCs. LZ, RW and YR participated in the design of the study and performed the statistical analysis. GC conceived of the study. All authors participated in its design and follow-up and helped to draft the manuscript. All authors read and approved the final manuscript. Declaration: The authors have no conflicting, interests, not supported or funded by any funds. We hope that the editorial board will agree on the interest of this study. Sincerely yours, Corresponding author: gecai,chen Adress: 399 Hailing Road, Taizhou Renmin Hospital, Taizhou, Jiangsu Province, China E-mai: [email protected] Phone number: +86-13914547274